Alvotech Announces Approval of AVT03, a Biosimilar to Prolia(R) and Xgeva(R) (denosumab) in the European Economic Area
(NasdaqGM:ALVO),(Nasdaq First North Iceland:ALVO),(Stockholm:ALVO SDB), REYKJAVIK, Iceland, Nov. 24, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Commission (EC) has approved AVT03 as a biosimilar to Prolia(R) and Xgeva(R) (denosumab). The European denosumab market is […]